CA2139127A1 - Compositions permettant d'inhiber la formation d'hormones proteiques et leur utilisation - Google Patents

Compositions permettant d'inhiber la formation d'hormones proteiques et leur utilisation

Info

Publication number
CA2139127A1
CA2139127A1 CA002139127A CA2139127A CA2139127A1 CA 2139127 A1 CA2139127 A1 CA 2139127A1 CA 002139127 A CA002139127 A CA 002139127A CA 2139127 A CA2139127 A CA 2139127A CA 2139127 A1 CA2139127 A1 CA 2139127A1
Authority
CA
Canada
Prior art keywords
tnf
protnf
convertase
val
mature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002139127A
Other languages
English (en)
Inventor
Michael Kriegler
Carl Perez
Robert F. Halenbeck
David A. Jewell
Kirston E. Koths
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2139127A1 publication Critical patent/CA2139127A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CA002139127A 1992-06-25 1993-06-25 Compositions permettant d'inhiber la formation d'hormones proteiques et leur utilisation Abandoned CA2139127A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90554692A 1992-06-25 1992-06-25
US07/905,546 1992-06-25

Publications (1)

Publication Number Publication Date
CA2139127A1 true CA2139127A1 (fr) 1994-01-06

Family

ID=25421021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002139127A Abandoned CA2139127A1 (fr) 1992-06-25 1993-06-25 Compositions permettant d'inhiber la formation d'hormones proteiques et leur utilisation

Country Status (4)

Country Link
EP (1) EP0648225A1 (fr)
JP (1) JPH07508650A (fr)
CA (1) CA2139127A1 (fr)
WO (1) WO1994000555A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5795859A (en) * 1991-07-05 1998-08-18 Peptide Technology Limited Peptide which abrogates TNF and/or LPS toxicity
EP0749494A1 (fr) 1994-03-07 1996-12-27 Chiron Corporation Compositions pour l'inhibition de la formation des facteurs de necrose tumorale (tnf) et leur utilisation
DK0830130T3 (da) * 1995-06-08 2004-12-20 Immunex Corp TNF-alfa-omdannende enzym
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
AU752369B2 (en) * 1995-06-08 2002-09-19 Immunex Corporation TNF-alpha converting enzyme
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
CN1310675C (zh) * 1995-07-20 2007-04-18 依默耐克斯有限公司 TNF－α转变酶
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
EP1103607A1 (fr) * 1999-11-23 2001-05-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Augmentation des niveaux de tmTNF pour la sensibilisation des tumeurs contre sTNF et/ou des composés cytotoxiques
FR2826581B1 (fr) * 2001-06-29 2005-10-07 Oreal Utilisation du tripeptide lys-pro-val (kpv) dans le traitement des melanomes
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
PE20211236A1 (es) * 2018-11-19 2021-07-09 Univ Texas Gen suicida

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750037A3 (fr) * 1989-08-16 1997-01-15 Cetus Oncology Corporation TNF-convertase et procédé pour la mesure d'inhibition de TNF-convertase

Also Published As

Publication number Publication date
WO1994000555A2 (fr) 1994-01-06
AU4991793A (en) 1994-01-24
WO1994000555A3 (fr) 1994-02-17
EP0648225A1 (fr) 1995-04-19
AU687751B2 (en) 1998-03-05
JPH07508650A (ja) 1995-09-28

Similar Documents

Publication Publication Date Title
EP0600880B1 (fr) Interleukine 1-beta protease et inhibiteurs d'interleukine 1-beta protease
FI88932B (fi) Framstaellning av funktionellt maenskligt urokinasprotein
JPH09505721A (ja) インターロイキン６レセプターアンタゴニスト
CA2139127A1 (fr) Compositions permettant d'inhiber la formation d'hormones proteiques et leur utilisation
US6245739B1 (en) polypeptides and polypeptide analogues
WO1991015577A1 (fr) INTERLEUKIN 1'beta' PROTEASE
US5602102A (en) Dipeptidyl peptidase-I inhibitors and uses thereof
EP0491878B1 (fr) Compositions pour l'inhibition de la formation d'hormones proteiques et emplois de celles-ci
US5643752A (en) Tissue inhibitor of metalloproteinases
US6599706B1 (en) Recombinant PR-3 and assays employing the same
JP2002515020A (ja) ＴＮＦ−α転換酵素
CA2343720A1 (fr) Nouveaux anticorps, medicaments les contenant et methodes de criblage de composes par utilisation desdits anticorps
US5998378A (en) Compositions for the inhibition of TNF hormone formation and uses thereof
US4973555A (en) Human serine protease gene
US5843693A (en) Assay method for screening for inhibitors of proTNF conversion
WO1995009913A9 (fr) Inhibiteur de metalloproteases derive de monocytes/macrophages humains
WO1995009913A1 (fr) Inhibiteur de metalloproteases derive de monocytes/macrophages humains
US6586222B1 (en) Recombinant PR-3 and compositions thereof
AU687751C (en) Compositions for the inhibition of protein hormone formation and uses therof
US6586225B2 (en) ICE/CED-3 like protease designated FMH-1
US5213977A (en) Serine protease from cytotoxic killer cells
AU619803B2 (en) Rearranged tissue plasminogen activators and method for producing same
BG60507B2 (bg) Човешки тъканен плазминогенен активатор
JP2001286289A (ja) トロンボスポンジンドメインを有する新規メタロプロテアーゼとこれをコードする核酸組成物

Legal Events

Date Code Title Description
FZDE Dead